[Evaluation of treatment for the prevention of acute gastric lesions in stress, in rats].

OBJECTIVE

To verify wether a cytoprotective or a antisecretant drug is effective on stress acute gastric.

METHOD: Female Wistar rats (n=7), 200 g, 24 h fasted, water ad lib. were used. Experiment I. Stress (s) by immobilization and immersion in 181/3 C water, 6 h (control). 30 min pretreatment with 2 ml 800 mg/Kg in OG bolus Sucralfate. 800 mg/Kg OG Magaldrate. 800 mg/Kg OG AIMgOH. 800 mg/Kg OH Hydrotalcite. 100 aeg/Kg OG Misoprostol (antisecretant). 125 mg/Kg s.c. Somatostatine (Octeotride). 30 mg/Kg i.p. Ranitidine. 30 mg/Kg i.p. Omeprazole and 30 mg/Kg i.p. Lanzoprazole. The rats were sacrificed by ether overdose, and laparotomy was performed to remove stomach and to assess the percentage gastric lesional area by computerized planimetry and histological examination. Experiment II. With the same scheme above described and previous anesthesia, laparatomy and pylorus ligature, the acid gastric secretion was studied. Results Exp. I. Percentage of gastric lesional area: C: 80.5 +/- 5.1; Sucralfate: 25.6 +/- 4.1 (p < 0.05). Magaldrate: 51.6 +/- 7.1 (NS). AIMgOH 78.6 +/- 7.1. Hydrotalcite; 85.6 +/- 5.1. Misoprostol (cytoprotector) 59.5 +/- 6.1 (NS). Misoprostol (antisecretant) 1 +/- 0.1 (p < 0.001). Somatostatine: 20.3 +/- 5.1 (p < 0.01). Ranitidine: 46.5 +/- 7.8 (NS). Omeprazole: 1 +/- 0.1 and Lanzoprazole: 1 +/- 0.1 (p < 0.001). Histological examination demonstrated gastric cytoprotection in the groups pretreated with Omeprazole and Lanzoprazole. Exp. II. 6 h m/Mol HCl output: C: 0.22 +/- 0.09. Sucralfate: 0.2 +2- 0.07 (NS). Magaldrate: 0.19 +/- 0.08. AIMgOH: 0.18 +/- 0.07. Hydrotalcite: 0.19 +/- +/- 0.10. Misoprostol (cytoprotector): 0.23 +/- 0.07. Misoprostol (anti-secretor): 0.11 +2- 0.05 (p < 0.05). Somatostatin: 0.09 +/- 0.04. Ranitidine: 0.08 +/- 0.05. Omeprazole: 0.02 +/- 0.01 (p < 0.001) and Lanzoprazole: 0.02 +/- 0.01.

CONCLUSION

In the prevention of stress acute gastric lesions Sucralfate might be indicated as a partial cytoprotector and Omeprazole or Lanzoprazole as antisecretant and lesion preventive drugs.